ERROR! No headcode.htm file found.

School of Medicine


Showing 21-40 of 46 Results

  • Michael Link

    Michael Link

    Lydia J. Lee Professor in Pediatric Cancer

    Current Research and Scholarly Interests Hematology/Oncology, treatment of sarcomas of bone and soft tissue, biology of acute lymphoblastic leukemias, treatment of non-Hodgkin's lymphoma and Hodgkin's disease.

  • Clara Lo

    Clara Lo

    Clinical Associate Professor, Pediatrics - Hematology & Oncology

    Current Research and Scholarly Interests Research interests include:
    Biomarkers and targeted therapy in pediatric immune thrombocytopenia
    Transfusion-related iron overload
    Hemophilia and other rare bleeding disorders
    Thrombophilia

  • Crystal Mackall

    Crystal Mackall

    Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine

    Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that genetically engineered T cells can eradicate cancers resistant to all other therapies. We are identifying new targets for these therapeutics, exploring pathways of resistance to current cell therapies and creating next generation platforms to overcome therapeutic resistance. We have discovered novel insights into the biology of human T cell exhaustion and developed approaches to prevent and reverse this phenomenon.

  • Robbie Majzner

    Robbie Majzner

    Assistant Professor of Pediatrics (Hematology/Oncology)

    Bio Robbie Majzner is an Assistant Professor of Pediatrics in the Division of Hematology and Oncology. After graduating with a BA from Columbia University, Dr. Majzner attended Harvard Medical School, where he developed an interest in pediatric oncology. He completed his residency training in pediatrics at New York Presbyterian-Columbia and fellowship training in pediatric hematology-oncology at Johns Hopkins and the National Cancer Institute. During his fellowship, he cared for some of the first pediatric patients to receive CD19 chimeric antigen receptor (CAR) T cells, children with B cell acute lymphoblastic leukemia (B-ALL) who often had no other therapeutic option. Witnessing the success of CAR T cells in these patients drove Dr. Majzner to the laboratory, where he focuses on extending the use of CAR T cells to solid tumors. He has generated and optimized novel receptors to recognize antigens over-expressed on pediatric solid tumors such as GD2 (Mount/Majzner et al., Nature Medicine, 2018) B7-H3 (Majzner et al., Clinical Cancer Research, 2019), and ALK (Walker/Majzner et al., Molecular Therapy, 2017). Current work focuses on imparting multi-specificity to CAR T cells and optimizing these receptors to enhance their efficacy when the amount of target (antigen density) is limiting (Majzner et al., Cancer Discovery, 2020). By drawing on state of the art bioengineering techniques, the Majzner Laboratory focuses on enhancing the potency and specificity of CAR T cells for children with cancer.

    Clinically, Dr. Majzner cares for all patients with neuroblastoma at the Lucile Packard Children's Hospital and has a specific interest in bringing novel immunotherapies to clinical trials for these patients and those with other solid tumors. He is board certified in pediatrics and pediatric hematology-oncology.

  • Anupama Narla

    Anupama Narla

    Assistant Professor of Pediatrics (Hematology/Oncology)

    Current Research and Scholarly Interests My research interests are to study the pathophysiology of ribosomopathies and to translate these insights into the work-up and management of pediatric bone marrow failure syndromes.

  • Allison Pribnow

    Allison Pribnow

    Clinical Assistant Professor, Pediatrics - Hematology & Oncology

    Current Research and Scholarly Interests Solid Tumors, Bone Sarcomas, Global Oncology, Health Disparities

  • Sneha Ramakrishna

    Sneha Ramakrishna

    Instructor, Pediatrics - Hematology & Oncology

    Bio Sneha Ramakrishna, M.D., is an Instructor of Pediatrics in the Division of Hematology and Oncology, working with Dr Crystal Mackall. Dr. Ramakrishna obtained her B. A. from the University of Chicago and her M.D. from the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. She completed her residency training in Pediatrics at the Children?s Hospital of Philadelphia and her fellowship in Pediatric Hematology/Oncology at the Johns Hopkins/National Cancer Institute combined program. Her research focuses on identifying mechanisms of relapse in patients following chimeric antigen receptor (CAR) T cell therapies and optimizing both CAR design and tumor sensitivity to improve long-term success of CAR T cell therapies.

  • Julien Sage

    Julien Sage

    Elaine and John Chambers Professor of Pediatric Cancer and Professor of Genetics

    Current Research and Scholarly Interests We investigate the mechanisms by which normal cells become tumor cells, and we combine genetics, genomics, and proteomics approaches to investigate the differences between the proliferative response in response to injury and the hyperproliferative phenotype of cancer cells and to identify novel therapeutic targets in cancer cells.

  • Kathleen M. Sakamoto

    Kathleen M. Sakamoto

    Shelagh Galligan Professor in the School of Medicine

    Current Research and Scholarly Interests My research focuses on the molecular pathways that regulate normal and aberrant blood cell development, including acute leukemia and bone marrow failure syndromes. We are also studying novel drugs for treatment of cancer.

  • Liora Schultz

    Liora Schultz

    Clinical Assistant Professor, Pediatrics - Hematology & Oncology

    Bio I am currently postdoctoral research fellow pursuing immunotherapy research in the oncology department at Stanford University. My clinical training as a pediatric hematology oncology fellow at Memorial Sloan Kettering Cancer Center highlighted the desperate need for novel therapeutic options for a subtype of aggressive pediatric leukemia, Acute Myeloid Leukemia (AML). Despite our best standard of care for AML, long term survival rates range from 50-60% with an unacceptably high relapse rate of 40%. The urgent need for novel treatments inspired me to pursue a research project in adoptive immunotherapy, genetically modifying Tcells to express artificial T cell receptors, termed chimeric antigen receptors (CARs), that target AML specific antigens. In parallel to my clinical training, I constructed an AML specific CAR and demonstrated its ability to redirect T cell function mediating eradication of AML cells. As the field of CAR therapy rapidly advances, novel methods to optimize this therapeutic modality are imperative. To this end, supported by research demonstrating superior antitumor function of naïve derived effector T cells compared to central memory derived effector T cells, I am investigating whether preferential modification of naïve T cells to express CARs will generate a T cell subpopulation with increased efficacy. Consolidating my clinical and research experiences within highly academic institutes allows me to synthesize my pursuit of scientific rigor and commitment to the field of oncology, with a mission to achieve productive research and translatable results.

  • Stephanie Melissa Smith

    Stephanie Melissa Smith

    Instructor, Pediatrics - Hematology & Oncology

    Current Research and Scholarly Interests I am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments. My current research relates to the use of BCR-ABL tyrosine kinase inhibitors for CML and Ph+ ALL, as little is known about the long-term and late effects of these therapies in young people. I also collaborated with several others to develop an online cancer survivorship course for primary care physicians and other healthcare providers.

  • Sheri Spunt

    Sheri Spunt

    Endowed Professor of Pediatric Cancer

    Current Research and Scholarly Interests My research focuses primarily on the management of children, adolescents, and young adults with soft tissue sarcomas. I also have an interest in developmental therapeutics and late effects of cancer therapy,

Stanford Medicine Resources: